Phase 2 Study to Assess the Safety, PK, and PD in SBS-IF Subjects
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled, proof-of-concept (PoC), Phase 2 study
to assess the safety, PK, and PD of SC administration of HM15912 in adult subjects with
SBS-associated intestinal failure (SBS-IF).